Sunbird Bio to Present Data from Study Evaluating Tau Blood-Based Biomarkers at the Alzheimer’s Association International Conference® 2024 (AAIC®)
11 Julio 2024 - 7:30AM
Business Wire
Sunbird Bio, a biotechnology company developing proprietary
blood-based technologies to improve diagnosis and treatment of
neurological disorders and early-stage cancer, today announced that
new findings from a study evaluating its blood-based diagnostic
platform will be presented at the Alzheimer’s Association
International Conference® 2024 (AAIC®) taking place July 28 –
August 1, 2024, in Philadelphia. The study explored the potential
of brain-derived, extracellular vesicle (EV)-bound tau proteins to
serve as robust blood-based biomarkers for the diagnosis of
neurodegenerative diseases including Alzheimer’s disease.
“As research continues to uncover the importance of tau proteins
in the diagnosis and treatment of Alzheimer’s disease, we’re
pleased to share our latest findings with the Alzheimer’s community
to build on this growing body of evidence,” said John McDonough,
executive chair and CEO of Sunbird Bio. “In prior studies, our team
has witnessed the remarkable potential of extracellular
vesicle-bound diseased proteins in the blood to accurately indicate
protein aggregation in the brain that denotes the presence of
disease. We are evaluating this potential in key neurodegenerative
disease biomarkers, including tau, with our diagnostic platform and
look forward to sharing more at this year’s conference.”
The accumulation of tau tangles in the brain is a hallmark
pathology of Alzheimer's disease, particularly in the later stages
of the disease. There are numerous therapeutics in development that
specifically target this protein, accentuating the urgent need for
accessible and accurate methods to detect aggregated tau proteins.
Sunbird Bio’s diagnostic platform is the first technology that
directly detects, from a simple blood draw, the EV-bound,
disease-specific proteins that aggregate in the brain and play a
key role in the pathogenesis of Alzheimer’s disease, including tau,
amyloid beta (Aβ), alpha synuclein (α-synuclein), and other protein
and non-protein biomarkers.
Following are details of the Sunbird Bio poster presentation at
AAIC:
- Topic: The potential of brain EV-bound proteins in blood
as a robust biomarker for accurate classification of tau tangles in
the brain
- Presenter: Nicholas Ho, Ph.D., head of innovation and
scientific co-founder, Sunbird Bio
- Date and Time: Tuesday, July 30, 2024, 8:00 a.m. ET –
4:15 p.m. ET
- Poster Number: #88533
About Sunbird Bio
Sunbird Bio is a biotechnology company developing proprietary
blood-based diagnostic tests that provide unprecedented insights to
enable earlier, more accurate diagnosis and treatment of
neurological disorders and early-stage cancer. Sunbird’s innovative
technologies uniquely detect the property and activity of proteins
to empower researchers and clinicians with actionable information
that is not available or accessible from current tests. Sunbird
Bio’s unparalleled leadership in blood-based diagnostics positions
the company to become a global leader in the field, addressing
significant research and clinical gaps, and serving multiple,
sizable markets. For more information, please visit
sunbirdbio.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240711300030/en/
Media Laura Morgan Sam Brown, Inc. 951.333.9110
lauramorgan@sambrown.com